SEC Form 4 · accession 0000921895-16-004321
CTI BIOPHARMA CORP · CTIC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew D Perry
Director · Other
Period of report
Apr 29, 2016
Accepted (ET)
May 3, 2016 · 5:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000891293
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F4,F2,F3 | — | Apr 29, 2016 | A | 347,360 | A | — | — | Common Stock | 347,360 | 431,394 | D |
Explanation of responses
- F1The Reporting Person may be deemed to be a member of a Section 13(d) group that may be deemed to collectively beneficially own more than 10% of the Issuer's outstanding shares of Common Stock.
- F2Each restricted stock unit represents the right to receive, at settlement, one share of CTIC common stock.
- F3This restricted stock unit was granted on April 29, 2016 and scheduled to vest twelve months after grant date or, if earlier, the first annual meeting of CTIC's shareholders in 2017 at which one or more members of the CTIC Board of Directors are to be elected.
- F4Total includes other awards that may have a different vesting date.